Lexeo Therapeutics, Inc. (LXEO) Stock Forecast & Price Target

Compare

162 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LXEO Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Lexeo

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LXEO Stock 12 Month Forecast

Average Price Target

$17.00

▲(265.59%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Lexeo Therapeutics, Inc. in the last 3 months. The average price target is $17.00 with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 265.59% change from the last price of $4.65.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,5.886153846153846,7.062307692307693,8.23846153846154,9.414615384615384,10.59076923076923,11.766923076923078,12.943076923076923,14.119230769230768,15.295384615384616,16.47153846153846,17.647692307692306,18.823846153846155,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,5.655384615384615,6.600769230769231,7.546153846153846,8.491538461538461,9.436923076923076,10.382307692307691,11.327692307692306,12.273076923076921,13.218461538461536,14.163846153846151,15.109230769230766,16.054615384615385,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,5.116923076923077,5.523846153846154,5.930769230769231,6.337692307692308,6.7446153846153845,7.151538461538461,7.558461538461539,7.9653846153846155,8.372307692307693,8.779230769230768,9.186153846153847,9.593076923076923,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.87,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$17.00

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leland GershellOppenheimer

Oppenheimer

$20

Buy

330.11%

Upside

Initiated

07/31/25

Lexeo Therapeutics initiated with an Outperform at OppenheimerLexeo Therapeutics initiated with an Outperform at Oppenheimer

Mani ForooharLeerink Partners

Leerink Partners

$16→$10

Buy

115.05%

Upside

Reiterated

05/28/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$23→$15

Buy

222.58%

Upside

Reiterated

05/16/25

Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating

Geulah LivshitsChardan Capital

Chardan Capital

$22→$20

Buy

330.11%

Upside

Reiterated

05/12/25

Lexeo Therapeutics price target lowered to $20 from $22 at ChardanLexeo Therapeutics price target lowered to $20 from $22 at Chardan

Luca IssiRBC Capital

RBC Capital

$20

Buy

330.11%

Upside

Reiterated

05/12/25

Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital

Tessa RomeroJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

04/10/25

Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$21

Buy

351.61%

Upside

Reiterated

02/10/25

Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from Stifel Nicolaus

Brian SkorneyRobert W. Baird

Robert W. Baird

$28

Buy

502.15%

Upside

Reiterated

11/20/24

Lexeo Therapeutics' Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment Opportunity

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leland GershellOppenheimer

Oppenheimer

$20

Buy

330.11%

Upside

Initiated

07/31/25

Lexeo Therapeutics initiated with an Outperform at OppenheimerLexeo Therapeutics initiated with an Outperform at Oppenheimer

Mani ForooharLeerink Partners

Leerink Partners

$16→$10

Buy

115.05%

Upside

Reiterated

05/28/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$23→$15

Buy

222.58%

Upside

Reiterated

05/16/25

Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating

Geulah LivshitsChardan Capital

Chardan Capital

$22→$20

Buy

330.11%

Upside

Reiterated

05/12/25

Lexeo Therapeutics price target lowered to $20 from $22 at ChardanLexeo Therapeutics price target lowered to $20 from $22 at Chardan

Luca IssiRBC Capital

RBC Capital

$20

Buy

330.11%

Upside

Reiterated

05/12/25

Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital

Tessa RomeroJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

04/10/25

Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$21

Buy

351.61%

Upside

Reiterated

02/10/25

Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from Stifel Nicolaus

Brian SkorneyRobert W. Baird

Robert W. Baird

$28

Buy

502.15%

Upside

Reiterated

11/20/24

Lexeo Therapeutics' Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment Opportunity

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lexeo Therapeutics, Inc.

1 Month

xxx

Success Rate

6/12 ratings generated profit

Average Return

+12.98%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +12.98% per trade.

3 Months

xxx

Success Rate

6/12 ratings generated profit

Average Return

+12.09%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +12.09% per trade.

1 Year

Mitchell KapoorH.C. Wainwright

Success Rate

3/8 ratings generated profit

Average Return

-15.16%

reiterated a buy rating 3 months ago

Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -15.16% per trade.

2 Years

xxx

Success Rate

3/8 ratings generated profit

Average Return

-14.19%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -14.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LXEO Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LXEO has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LXEO average Analyst price target in the past 3 months is 17.00.

Each month's total comprises the sum of three months' worth of ratings.

LXEO Financial Forecast

LXEO Earnings Forecast

Next quarter’s earnings estimate for LXEO is -$0.67 with a range of -$0.81 to -$0.40. The previous quarter’s EPS was -$0.99. LXEO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.21% of the time in the same period. In the last calendar year LXEO has Outperformed its overall industry.

No data currently available

LXEO Sales Forecast

Next quarter’s sales forecast for LXEO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LXEO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.44% of the time in the same period. In the last calendar year LXEO has Preformed in-line its overall industry.

LXEO Stock Forecast FAQ

What is LXEO’s average 12-month price target, according to analysts?

Based on analyst ratings, Lexeo Therapeutics, Inc.’s 12-month average price target is 17.00.

What is LXEO’s upside potential, based on the analysts’ average price target?

Lexeo Therapeutics, Inc. has 265.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LXEO a Buy, Sell or Hold?

Lexeo Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Lexeo Therapeutics, Inc.’s price target?

The average price target for Lexeo Therapeutics, Inc. is 17.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 265.59% Increase from the current price of $4.65.

What do analysts say about Lexeo Therapeutics, Inc.?

Lexeo Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of LXEO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Lexeo Therapeutics, Inc. (LXEO) Stock Forecast & Price Target

LXEO Analyst Ratings

LXEO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Lexeo Therapeutics, Inc.

LXEO Analyst Recommendation Trends

LXEO Financial Forecast

LXEO Earnings Forecast

LXEO Sales Forecast

LXEO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts